Loading...
Defining the optimal duration and route of therapy for a number of infectious diseases without clinical trial data has been difficult, and options have been wide-ranging. Such has been the case for vertebral osteomyelitis.
In a recent multicenter, open-label, noninferiority, randomized, controlled trial, researchers in France compared 6 versus 12 weeks of therapy in adults with vertebral osteomyelitis caused by bacteria other than Mycobacterium and Brucella species. The primary endpoint was cure of infection 1 year after the end of antibiotic therapy in the intent-to-treat population.
In all, 160 (90.9%) of 176 patients in the 6-week group and 159 (90.8%) of 175 patients in the 12-week group achieved clinical cure (difference, 0.05%; 95% conf…